VRTX Pharmaceuticals, Inc. is a biotech company that works on finding, creating, making, and selling small molecule drugs for people with serious diseases. It is based in Boston, MA and was started by Joshua S. Boger in 1989. The company focuses on developing treatments for diseases such as cystic fibrosis, sickle cell disease, pain, and cancer.
The VRTX stock’s latest quarterly report for the period ending June 2023 showed a revenue of $2.48 Billion, a net income of $915.70 Million, and a profit margin of 36.85%. The next quarter’s revenue is estimated to be $2.499 Billion. Vertex reported an EPS of $3.89 for the second quarter, beating analysts’ estimate of $3.859 by 0.80%. The next quarter’s EPS is estimated to be $3.925.
Vertex Group will announce its financial results for the third quarter of 2023 on Wednesday, November 1st, 2023, before the market opens. The Vertex stock’s most recent quarterly balance sheet for the period ending June 2023 showed total assets at $20.35 Billion and total liabilities at $4.88 billion.
The VRTX stock has a float of 257.177 Million shares and a market cap of $90.212 Billion. The Vertex stock’s earnings per share (EPS) for the trailing twelve months (TTM) is 13.09 and its price-to-earnings ratio (P/E) for the same period is 27.39. The Vertex stock has a CMP of $349.53 and an intraday gain of 1.00%. The stock’s average volume for the last 10 days is 908.452 K and its current volume is 938.793 K.
VRTX Stock Price Technical Analysis in 1-D Time Frame
The share price of Vertex has been impressive in the past years, with a strong upward trend that began in January 2017 from $71 and continued as more investors trusted and invested in the company. However, during the pandemic, the price dropped from its peak of $300 to $160. But, after October 2021, this setback was over and the price bounced back and rose remarkably, following the trendline support.
Over the last couple of years, the stock displayed a positive performance on year-to-date growth of 21.11% and a modest six-month increase of 14.46%.
The price is consolidating between the 20-day and 50-day EMAs at press time. The MACD highlights a bullish cross but with lean histogram and RSI at 50 indicate same consolidation in price over the charts.
Moreover, the stock ratings for Vertex stock are very positive and highly recommended by 32 analysts who have evaluated it in the last three months. The 1-year price forecast for Vertex stock by 25 analysts ranges from $315 to $456, with a high potential for growth.
The Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) chart indicates that the traders and investors of the VRTX stock price are neutral to bullish on the 1-D time frame. The price action shows a bullish outlook at the time of publishing. Technicals are giving bullish signals.
Support levels: $339 and $335
Resistance levels: $358 and $366
In this article, the views and opinions stated by the author, or any people named are for informational purposes only, and they don’t establish the investment, financial, or any other advice. Trading or investing in cryptocurrency assets comes with a risk of financial loss.